Johns Hopkins School of Medicine

Bicycle Therapeutics Enhances Leadership Team with Key Appointments

Retrieved on: 
Monday, April 3, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31.
  • Dr. Arroyo brings to Bicycle over 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease areas.
  • “We are thrilled to have Santiago on board in the new role of Chief Development Officer at Bicycle as we prepare to transition into a late-stage development organization,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • “We wish him every success in his future endeavors.”
    Dr. Arroyo was most recently the Chief Medical Officer of Fulcrum Therapeutics.

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

Retrieved on: 
Tuesday, April 4, 2023

In total, there will be five presentations at AACR, four of which build on previous positive data for paxalisib in melanoma and childhood brain cancer.

Key Points: 
  • In total, there will be five presentations at AACR, four of which build on previous positive data for paxalisib in melanoma and childhood brain cancer.
  • The new data being presented provide significant support and direction for the future development of paxalisib in these expansion indications.
  • In addition, a presentation by scientists from Kazia's partner, Evotec, will outline the novel biomarker strategy employed in the phase I study of EVT801, and anticipates the potential initial clinical data from EVT801 in CY2023.
  • This data expands on positive data for paxalisib as monotherapy and in other combination regimens that was presented at AACR in 2022.

 RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

Retrieved on: 
Thursday, March 30, 2023

The interim analysis shows a 6-month median overall survival benefit for patients.

Key Points: 
  • The interim analysis shows a 6-month median overall survival benefit for patients.
  • TIGeR-PaC study Principal Investigator, Michael J. Pishvaian, M.D., Ph.D. at Johns Hopkins Medicine, said, “Results from the interim analysis echo the Phase I/II data and observational studies.
  • It is worth noting that ten years ago, Celgene announced positive, Phase III trial results for pancreatic cancer patients.
  • RenovoRx CEO, Shaun Bagai, commented, “We are more than a third way through our Phase III TIGeR-PaC study and are encouraged by these data.

Ellipses Pharma: Expansion of Scientific Affairs Group

Retrieved on: 
Thursday, March 30, 2023

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG).

Key Points: 
  • Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG).
  • Ellipses now has more than 200 oncology experts from 106 institutions worldwide providing analysis and advice on selection of the most promising potential cancer medicines.
  • Ellipses has built a cloud-based platform to crowdsource scientific and clinical insight from its key opinion leaders (KOLs) that allows them to provide responses anonymously.
  • “We are delighted and very proud that so many eminent oncologists from around the world have enthusiastically embraced what we believe is the largest scientific affairs group in oncology and a unique model.

Florence Launches Modern Healthcare Experience With $20M Seed Round Led by Thrive Capital, GV, and Salesforce Ventures

Retrieved on: 
Thursday, March 30, 2023

NEW YORK, March 30, 2023 /PRNewswire/ -- Florence, an innovator in healthcare enablement software, has launched out of stealth mode after raising $20 million in seed funding. The health tech startup's round was led by Thrive Capital, GV (Google Ventures), and Salesforce Ventures with participation from Vast Ventures, BoxGroup and Atento Capital.

Key Points: 
  • The health tech startup's round was led by Thrive Capital, GV (Google Ventures), and Salesforce Ventures with participation from Vast Ventures, BoxGroup and Atento Capital.
  • Comprised of physicians and engineers from leading health systems and technology companies, the Florence team has created a technology solution that provides a modern consumer experience while reducing operational overhead.
  • The technology drives efficiency for healthcare workers and patients, enabling patients to get care faster while load-balancing in-person and virtual capacity across health systems and clinics.
  • "Technology is the most expedient way to address the growing challenges to our overburdened healthcare system across cost, access and labor," said Aniq Rahman, Florence CEO and Founder.

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Retrieved on: 
Thursday, March 23, 2023

LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Key Points: 
  • The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
  • This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."
  • Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer.
  • Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board.

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

Retrieved on: 
Thursday, March 23, 2023

LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Key Points: 
  • The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
  • This is the first of our presidential appointments and we look forward to providing updates on further appointments in due course."
  • Samson joined Clarivate in October 2020 with the acquisition of CPA Global, having joined CPA Global in 2014 as Chief Operating Officer.
  • Andy Snyder, Chairman of the Board, Clarivate commented: "We look forward to Dr. Saha joining our Board.

Atropos Health Announces Clinical Advisory Board to Further Deliver its Promise on Bringing Real-World Evidence to Healthcare

Retrieved on: 
Thursday, March 23, 2023

PALO ALTO, Calif., March 23, 2023 /PRNewswire/ -- Atropos Health, the leader in generating personalized real-world evidence at the point and pace of care, today announced a newly formed Clinical Advisory Board consisting of physicians and executives from Stanford Health Care, John Hopkins Medicine, University of North Carolina Health, and more. The Clinical Advisory Board will further Atropos Health's mission of providing health systems and data companies alike with access to rapid, real-world medical evidence and actionable insights.

Key Points: 
  • The Clinical Advisory Board will further Atropos Health's mission of providing health systems and data companies alike with access to rapid, real-world medical evidence and actionable insights.
  • The Clinical Advisory Board consists of ten inaugural members, led by Chair, Dr. Nick Patel.
  • "Atropos Health has transformed healthcare research and delivery by breaking down barriers to data access and creating an observational insights exchange," said Dr. Patel.
  • Atropos Health's Clinical Advisory Board Members:
    Nick Patel MD - Chair of Advisory Board.

H1 Expands HCP Universe to Help Medical Affairs Understand and Track the Impact of Their Activities, Drive Adherence to Evidence-based Medicine, and Improve Patient Outcomes

Retrieved on: 
Tuesday, March 21, 2023

According to Johns Hopkins Medicine , evidence-based medicine is the cornerstone of clinical practice and can improve patient outcomes and quality of care.

Key Points: 
  • According to Johns Hopkins Medicine , evidence-based medicine is the cornerstone of clinical practice and can improve patient outcomes and quality of care.
  • HCP Universe will enable medical affairs teams to successfully engage HCPs and measure how their efforts are changing clinical behavior and improving patient outcomes.
  • We want the same because it will improve patient outcomes, quality of life, and access to equitable healthcare.
  • For more information on how H1 can help Medical Affairs track and measure impact, visit us here or to request a meeting with H1 during an upcoming conference, contact [email protected].

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Retrieved on: 
Saturday, March 18, 2023

Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.

Key Points: 
  • Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.
  • The phase III OLYMPIA 2 trial met all primary endpoints, showing nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions compared with placebo in adult patients with moderate to severe prurigo nodularis.
  • “We are so pleased that we’re able to bring so much powerful new data to this year’s AAD congress.
  • Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD.